PhaseBio files for bankruptcy, has a potential deal to sell its assets for up to $100M


The company is being sued by the development partner for its lead new drug candidate.

Previous 2022 Best Places to Work: Hylant in Lake Mary says its family-focused culture keeps employees engaged
Next Holiday Market at Snowport doubles in size for 2nd year, with 120 vendors